Patients’ characteristics and outcome after nivolumab discontinuation
| . | Remissions (n = 7) . | Toxicities (n = 4) . | All (N = 11) . | |||
|---|---|---|---|---|---|---|
| No. . | % . | No. . | % . | No. . | % . | |
| Characteristics at initiation of nivolumab | ||||||
| Median age (range), y | 33 (19-66) | 35.5 (26-53) | 33 (19-66) | |||
| Sex | ||||||
| Male | 4 | 43 | 3 | 75 | 7 | 64 |
| Female | 3 | 57 | 1 | 25 | 4 | 36 |
| Disease stage | ||||||
| I | 1 | 14 | 0 | 1 | 9 | |
| II | 2 | 29 | 0 | 2 | 18 | |
| IV | 4 | 57 | 3 | 75 | 7 | 64 |
| Unknown | 0 | 1 | 25 | 1 | 9 | |
| B symptoms | ||||||
| No | 6 | 86 | 4 | 100 | 10 | 91 |
| Missing | 1 | 0 | 1 | |||
| Prior lines of systemic therapy | ||||||
| 3 | 1 | 14 | 0 | 1 | 9 | |
| 4 | 2 | 29 | 0 | 2 | 18 | |
| 5 | 0 | 1 | 25 | 1 | 9 | |
| 6 | 1 | 14 | 0 | 1 | 9 | |
| ≥7 | 3 | 43 | 3 | 75 | 6 | 55 |
| Prior radiation therapy | 4 | 57 | 2 | 50 | 6 | 55 |
| Prior treatment with brentuximab vedotin | 7 | 100 | 4 | 100 | 11 | 100 |
| Prior autologous SCT | 4 | 57 | 3 | 75 | 7 | 64 |
| Prior allogeneic SCT | 2 | 29 | 3 | 75 | 5 | 46 |
| Anti-PD-1 treatment, discontinuation, and outcome | ||||||
| Median No. of nivolumab injections (range) | 28 (5-51) | 1.5 (1-5) | 10 (1-51) | |||
| Median duration of anti-PD-1 therapy (range), mo | 13.8 (4.8-24.1) | 0.2 (0-1.8) | 5.7 (0-24.1) | |||
| Concomitant radiotherapy | 2 | 29 | 0 | 2 | 18 | |
| Reason for nivolumab discontinuation | ||||||
| Prolonged remission | 7 | 100 | — | 7 | 64 | |
| Toxicity | — | 4 | 100 | 4 | 36 | |
| Acute GVHD | — | 2 | 2 | |||
| Cerebellar syndrome | — | 1 | 1 | |||
| Laryngeal oppression | — | 1 | 1 | |||
| CR at anti-PD-1 discontinuation4 | 7 | 100 | 4 | 100 | 11 | 100 |
| Median duration between first CR upon nivolumab and anti-PD-1 discontinuation (range), mo | 9.7 (3-22.4) | — | 9.7 (3-22.4) | |||
| Median follow-up from anti-PD-1 discontinuation (range), mo | 14.7 (4.2-29) | 25.6 (3.2-29.3) | 21.2 (3.2-29.3) | |||
| Patients alive at last follow-up | 7 | 100 | 3 | 75 | 10 | 91 |
| Patients in CR at last follow-up among patients alive | 6 | 86 | 2 | 67 | 8 | 80 |
| Retreatment with anti-PD-1 monotherapy among relapsed patients | 1 | 1 | 1 | 1 | 2 | 2 |
| Response to retreatment with anti-PD-1 in relapsed patients | ||||||
| CR | 0 | 0 | 0 | |||
| PR | 1 | 15 | 2 | |||
| . | Remissions (n = 7) . | Toxicities (n = 4) . | All (N = 11) . | |||
|---|---|---|---|---|---|---|
| No. . | % . | No. . | % . | No. . | % . | |
| Characteristics at initiation of nivolumab | ||||||
| Median age (range), y | 33 (19-66) | 35.5 (26-53) | 33 (19-66) | |||
| Sex | ||||||
| Male | 4 | 43 | 3 | 75 | 7 | 64 |
| Female | 3 | 57 | 1 | 25 | 4 | 36 |
| Disease stage | ||||||
| I | 1 | 14 | 0 | 1 | 9 | |
| II | 2 | 29 | 0 | 2 | 18 | |
| IV | 4 | 57 | 3 | 75 | 7 | 64 |
| Unknown | 0 | 1 | 25 | 1 | 9 | |
| B symptoms | ||||||
| No | 6 | 86 | 4 | 100 | 10 | 91 |
| Missing | 1 | 0 | 1 | |||
| Prior lines of systemic therapy | ||||||
| 3 | 1 | 14 | 0 | 1 | 9 | |
| 4 | 2 | 29 | 0 | 2 | 18 | |
| 5 | 0 | 1 | 25 | 1 | 9 | |
| 6 | 1 | 14 | 0 | 1 | 9 | |
| ≥7 | 3 | 43 | 3 | 75 | 6 | 55 |
| Prior radiation therapy | 4 | 57 | 2 | 50 | 6 | 55 |
| Prior treatment with brentuximab vedotin | 7 | 100 | 4 | 100 | 11 | 100 |
| Prior autologous SCT | 4 | 57 | 3 | 75 | 7 | 64 |
| Prior allogeneic SCT | 2 | 29 | 3 | 75 | 5 | 46 |
| Anti-PD-1 treatment, discontinuation, and outcome | ||||||
| Median No. of nivolumab injections (range) | 28 (5-51) | 1.5 (1-5) | 10 (1-51) | |||
| Median duration of anti-PD-1 therapy (range), mo | 13.8 (4.8-24.1) | 0.2 (0-1.8) | 5.7 (0-24.1) | |||
| Concomitant radiotherapy | 2 | 29 | 0 | 2 | 18 | |
| Reason for nivolumab discontinuation | ||||||
| Prolonged remission | 7 | 100 | — | 7 | 64 | |
| Toxicity | — | 4 | 100 | 4 | 36 | |
| Acute GVHD | — | 2 | 2 | |||
| Cerebellar syndrome | — | 1 | 1 | |||
| Laryngeal oppression | — | 1 | 1 | |||
| CR at anti-PD-1 discontinuation4 | 7 | 100 | 4 | 100 | 11 | 100 |
| Median duration between first CR upon nivolumab and anti-PD-1 discontinuation (range), mo | 9.7 (3-22.4) | — | 9.7 (3-22.4) | |||
| Median follow-up from anti-PD-1 discontinuation (range), mo | 14.7 (4.2-29) | 25.6 (3.2-29.3) | 21.2 (3.2-29.3) | |||
| Patients alive at last follow-up | 7 | 100 | 3 | 75 | 10 | 91 |
| Patients in CR at last follow-up among patients alive | 6 | 86 | 2 | 67 | 8 | 80 |
| Retreatment with anti-PD-1 monotherapy among relapsed patients | 1 | 1 | 1 | 1 | 2 | 2 |
| Response to retreatment with anti-PD-1 in relapsed patients | ||||||
| CR | 0 | 0 | 0 | |||
| PR | 1 | 15 | 2 | |||
SCT, stem cell transplantation.